The Hows & Whys of Pancreatic & Hepatobiliary Imaging: An Update
Weekend Course
ORGANIZERS: Jeffrey Maki, Scott Reeder
Saturday, 03 June 2023
713A/B
08:00 -
11:45
Moderators: Hersh Chandarana & Takeshi Yokoo
Skill Level: Intermediate
Session Number: WE-02
CME Credit
Session Number: WE-02
Overview
Clinically focused session highlighting the imaging of pancreatic malignancy as well as diffuse and malignant hepatic disease. The session will include updates in MR imaging technique and quantitative biomarkers for hepatobiliary disease.
Target Audience
Practicing MR clinicians wishing to be updated on clinical pancreas and hepatobiliary imaging as well as new directions the field is heading to. MR researchers hoping to better understand the clinical landscape of pancreatic and hepatobiliary disease.
Educational Objectives
As a result of attending this course, participants should be able to:
- Identify underlying pathophysiology and develop clinical interpretive skills with respect to pancreatic malignancies;
- Explain how and why to image NASH and other diffuse liver disease; and
- Evaluate improved hepatobiliary MR imaging techniques and liver screening for hepatocellular carcinoma.
08:00 | | High-Risk Pancreas Clinic: What’s Behind the Imaging? Paul James |
08:25 | | Imaging the At-Risk Pancreas Ihab Kamel Keywords: Body: Digestive - Discuss
the rationale behind pancreatic cancer screening/surveillance in at risk
patients.
- Summarize
what we know to date regarding the role of clinical imaging at baseline and
subsequent follow ups.
- Emphasize
the value of novel high-resolution imaging techniques and careful image interpretation
in early detection of pancreatic cancer.
- Identify
challenges and gaps in knowledge related to pancreatic cancer
screening/surveillance.
- List
promising future approaches including precision
medicine using artificial
intelligence to incorporate family history, genetics, environment, clinical
imaging, and biomarkers. |
08:50 | | Technical Advances in Hepatobiliary MR Imaging Mustafa Bashir Keywords: Body: Liver This talk will describe technological solutions to enable high-quality hepatobiliary MRI. |
09:15 | | Role of Hepatic MR in the Management of Oligometastatic Disease SS Baijal |
09:40 | | Break & Meet the Teachers |
10:05 | | NASH: Clinical Relevance & Perspective Keyur Patel Keywords: Cross-organ: Metabolic disease, Body: Liver The global prevalence of non-alcoholic fatty liver disease (NAFLD) is estimated at 25%. Non-alcoholic steatohepatitis (NASH) affects ~20% of NAFLD patients leading to progressive liver fibrosis and cirrhosis. The incidence of liver decompensation, liver cancer, and death related to NASH cirrhosis is expected to increase 2-3 fold over the next decade. Liver biopsy is the reference for diagnosing NASH and fibrosis, but non-invasive serum tests and imaging tools are increasingly available for the diagnosis of advanced fibrosis. Current medical management for NASH includes lifestyle intervention and treatment of metabolic disease, but there are currently no FDA-approved compounds for NASH. |
10:30 | | Update on Quantitative Biomarkers for Liver Fibrosis Shintaro Ichikawa Keywords: Body: Liver, Contrast mechanisms: Diffusion, Contrast mechanisms: Elastography Cirrhosis is the most important risk factor
for hepatocellular carcinoma; therefore, it is important to accurately assess
advanced fibrosis. Liver biopsy remains the gold standard for diagnostic
evaluation of hepatic fibrosis. However, its invasive nature and high cost make
it difficult to perform repeatedly. MRI is a noninvasive imaging tool that can
evaluate hepatic fibrosis. There are several methods to assess hepatic fibrosis
on MRI. This talk will provide an overview of diagnostic methods for hepatic
fibrosis by MRI including uptake of gadoxetic acid, T1 mapping,
diffusion-weighted imaging including intravoxel incoherent motion, T1rho,
radiomics/ artificial intelligence, and MR elastography. |
10:55 | | Liver Fat & Iron Quantification: How I Do It Manuela Franca Keywords: Body: Liver, Image acquisition: Quantification MRI has been established as a powerful imaging tool to evaluate diffuse liver diseases. Liver MRI offers a comprehensive assessment of the different tissue components, providing quantitative imaging biomarkers for fat and iron quantification. Multi-echo chemical-shift encoded (MECSE) gradient echo MR sequences are now widely used for simultaneous quantification of hepatic steatosis and siderosis.In this session, the use of MECSE sequences for liver fat & iron quantification will be explained, in different clinical scenarios of diffuse liver diseases, giving some tips and tricks for the technical implementation, analysis, interpretation and clinical use of liver fat and iron MR quantification. |
11:20 | | Abbreviated MRI for HCC Screening: Extracellular vs. Hepatobiliary Agents Bachir Taouli Keywords: Body: Liver In this presentation, we will discuss current guidelines for HCC screening/surveillance, and limitations of US screening, and the opportunities based on abbreviated MRI for this indication. Advantages and limitations of extracellular vs hepatobiliary gadolinium based contrast agents will be discussed. |